Cargando…

Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study

OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciccaglione, Antonio Francesco, Di Giulio, Mara, Di Lodovico, Silvia, Di Campli, Emanuela, Cellini, Luigina, Marzio, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419617/
https://www.ncbi.nlm.nih.gov/pubmed/30668729
http://dx.doi.org/10.1093/jac/dky510
_version_ 1783403982001012736
author Ciccaglione, Antonio Francesco
Di Giulio, Mara
Di Lodovico, Silvia
Di Campli, Emanuela
Cellini, Luigina
Marzio, Leonardo
author_facet Ciccaglione, Antonio Francesco
Di Giulio, Mara
Di Lodovico, Silvia
Di Campli, Emanuela
Cellini, Luigina
Marzio, Leonardo
author_sort Ciccaglione, Antonio Francesco
collection PubMed
description OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection. METHODS: The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [(13)C]urea breath test. RESULTS: In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10 mg/mL and expressed 50% bactericidal effect at 40 mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%–92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%–101.38%). CONCLUSIONS: Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect.
format Online
Article
Text
id pubmed-6419617
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64196172019-03-20 Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study Ciccaglione, Antonio Francesco Di Giulio, Mara Di Lodovico, Silvia Di Campli, Emanuela Cellini, Luigina Marzio, Leonardo J Antimicrob Chemother Original Research OBJECTIVES: To evaluate the in vitro antimicrobial/antivirulence action of bovine lactoferrin and its ability to synergize with levofloxacin against resistant Helicobacter pylori strains and to analyse the effect of levofloxacin, amoxicillin and esomeprazole with and without bovine lactoferrin as the first-line treatment for H. pylori infection. METHODS: The bovine lactoferrin antimicrobial/antivirulence effect was analysed in vitro by MIC/MBC determination and twitching motility against six clinical H. pylori strains and a reference strain. The synergism was evaluated using the chequerboard assay. The prospective therapeutic trial was carried out on two separate patient groups, one treated with esomeprazole/amoxicillin/levofloxacin and the other with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin. Treatment outcome was determined with the [(13)C]urea breath test. RESULTS: In vitro, bovine lactoferrin inhibited the growth of 50% of strains at 10 mg/mL and expressed 50% bactericidal effect at 40 mg/mL. The combination of levofloxacin and bovine lactoferrin displayed a synergistic effect for all strains, with the best MIC reduction of 16- and 32-fold for levofloxacin and bovine lactoferrin, respectively. Bovine lactoferrin at one-fourth MIC reduced microbial motility significantly for all strains studied. In the in vivo study, 6 of 24 patients recruited had treatment failure recorded with esomeprazole/amoxicillin/levofloxacin (75% success, 95% CI 57.68%–92.32%), and in the group with esomeprazole/amoxicillin/levofloxacin/bovine lactoferrin, 2 out of 53 patients recruited had failure recorded (96.07% success, 95% CI 90.62%–101.38%). CONCLUSIONS: Bovine lactoferrin can be considered a novel potentiator for restoring susceptibility in resistant H. pylori strains. Bovine lactoferrin added to a triple therapy in first-line treatment potentiates the therapeutic effect. Oxford University Press 2019-04 2019-01-21 /pmc/articles/PMC6419617/ /pubmed/30668729 http://dx.doi.org/10.1093/jac/dky510 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Research
Ciccaglione, Antonio Francesco
Di Giulio, Mara
Di Lodovico, Silvia
Di Campli, Emanuela
Cellini, Luigina
Marzio, Leonardo
Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title_full Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title_fullStr Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title_full_unstemmed Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title_short Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study
title_sort bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of helicobacter pylori infection: an in vitro and in vivo study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419617/
https://www.ncbi.nlm.nih.gov/pubmed/30668729
http://dx.doi.org/10.1093/jac/dky510
work_keys_str_mv AT ciccaglioneantoniofrancesco bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy
AT digiuliomara bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy
AT dilodovicosilvia bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy
AT dicampliemanuela bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy
AT celliniluigina bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy
AT marzioleonardo bovinelactoferrinenhancestheefficacyoflevofloxacinbasedtripletherapyasfirstlinetreatmentofhelicobacterpyloriinfectionaninvitroandinvivostudy